- Home
- CFLT vs ROIV Comparison
CFLT vs ROIV Comparison
Compare CFLT & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CFLT
- ROIV
- Stock Information
- Founded
- CFLT 2014
- ROIV 2014
- Country
- CFLT United States
- ROIV United Kingdom
- Employees
- CFLT N/A
- ROIV N/A
- Industry
- CFLT EDP Services
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- CFLT Technology
- ROIV Health Care
- Exchange
- CFLT Nasdaq
- ROIV Nasdaq
- Market Cap
- CFLT 8.1B
- ROIV 8.4B
- IPO Year
- CFLT 2021
- ROIV N/A
- Fundamental
- Price
- CFLT $23.12
- ROIV $10.76
- Analyst Decision
- CFLT Buy
- ROIV Buy
- Analyst Count
- CFLT 30
- ROIV 4
- Target Price
- CFLT $31.00
- ROIV $17.50
- AVG Volume (30 Days)
- CFLT 6.8M
- ROIV 5.9M
- Earning Date
- CFLT 04-30-2025
- ROIV 05-29-2025
- Dividend Yield
- CFLT N/A
- ROIV N/A
- EPS Growth
- CFLT N/A
- ROIV N/A
- EPS
- CFLT N/A
- ROIV N/A
- Revenue
- CFLT $1,017,525,000.00
- ROIV $122,585,000.00
- Revenue This Year
- CFLT $21.73
- ROIV N/A
- Revenue Next Year
- CFLT $18.93
- ROIV N/A
- P/E Ratio
- CFLT N/A
- ROIV N/A
- Revenue Growth
- CFLT 24.11
- ROIV 140.04
- 52 Week Low
- CFLT $17.79
- ROIV $8.73
- 52 Week High
- CFLT $37.90
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- CFLT 54.42
- ROIV 49.33
- Support Level
- CFLT $20.46
- ROIV $10.58
- Resistance Level
- CFLT $24.50
- ROIV $11.77
- Average True Range (ATR)
- CFLT 1.09
- ROIV 0.34
- MACD
- CFLT 0.29
- ROIV -0.05
- Stochastic Oscillator
- CFLT 74.44
- ROIV 15.13
About CFLT Confluent Inc.
Confluent Inc provides a data streaming platform that enables customers to connect their applications, systems, and data layers and can be deployed as a fully managed cloud-native software-as-a-service (SaaS) offering. Its products include Confluent Cloud, a self-managed software offering, Confluent Platform, a managed service offering where the raw data resides inside a customer's cloud environment, and WarpStream, among others. Confluent also offers professional services and education services. The company generates revenue from the sale of subscriptions and services. Geographically, it generates a majority of its revenue from its business in the United States and the rest from International markets.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.